Sonnet BioTherapeutics Regains Compliance With Nasdaq

Benzinga · 10/17 12:49

Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that it received notice on October 16, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") that the Company regained compliance with the bid price requirement in Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on the Nasdaq Capital Market.